Press Releases Events & Presentations Event Details EASL 2024 – The International Liver Congress Jun 5 - Jun 8, 2024 Supporting Materials ABI-6250 - Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis D 334.9 KB Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
EASL 2024 – The International Liver Congress Jun 5 - Jun 8, 2024 Supporting Materials ABI-6250 - Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis D 334.9 KB
ABI-6250 - Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis D 334.9 KB
